Alnylam Pharmaceuticals is an American biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The ticker symbol for Alnylam is ALNY. The stock jumped more than 68% in the last few weeks, gaining more than $10B in market cap, reaching $28B as of Aug 12, 2022.
Today we’ll learn what is RNAi and why therapeutic breakthroughs using RNAi are transforming Alnylam into a leading biotech company.
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine to Andrew Fire and Craig Mello.
Since its founding 20 years ago, Alnylam has led the translation of (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet needs. Today Alnylam continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA™ (vutrisiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis.
#Alnylam
#ALNY
#RNAI
#ATTR
#siRNA
#Polyneuropathy
#Cardiomyopathy
#hATTR
#Onpattro
#Patisiran
Join Robinhood with my link and we'll both get a free stock 🤝
join.robinhood...
***Disclaimer
I (Biotech Investor) hold a Ph.D. degree in life science and conducted 5 years of postdoctoral training in molecular biophysics at UC Berkeley. I am currently a full-time employee of a clinical-stage biopharmaceutical company, conducting early-stage drug discovery research. I have no professional affiliation with any of the companies or stocks discussed on this channel. This video is strictly for educational and entertainment purposes, and none of the contents in the video are for medical or financial/investment advice. I have no obligation to update, change or correct any information described in this video as news and stock prices change. The thoughts described in this channel are my own and do not reflect the company that I work for. This is not a solicitation to invest in any company I discussed in this channel, and I am not a financial or medical advisor. Investment involves risks and past performance should not be used as a gauge for future success. Seek a financial advisor to determine the appropriate investment strategies for your given circumstances. Investors should obtain their own independent financial advice and understand the risks associated with investment products/ services before making investment decisions.
2 окт 2024
